FDA Logo links to FDA home page
U.S. Food and Drug Administration
HHS Logo links to Department of Health and Human Services home page

FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA

horizontal rule

HIV and AIDS
Human Immunodeficiency Virus and
Acquired Immunodeficiency Syndrome

Advisory Committee Meetings related to HIV/AIDS
and associated conditions

For up-to-date information about upcoming FDA Advisory Committee meetings, please use the FDA Advisory Committe Information Line. The service provides recorded messages with date, location, and topic information about upcoming meetings.

Search by Medication/Topic or by year

Search by year
1996  |  1997  |  1998  |  1999  |  2000  |  2001  |  2002  |  2003 |  2004 |  2005 |  2006 |  2007

Search FDA Advisory Committee page
 for other topics and resources

Viewing Files

2007

Topic: Isentress (raltegravir potassium), integrase inhibitor 400 milligram tablets (NDA) 22-145 , Merck & Co., Inc., for the treatment of Human Immunodeficiency Virus-1 (HIV-1) infection in combination with other antiretroviral agents in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.
Date:9/5/2007

Committee: Antiviral Drugs Advisory Committee

Topic: Selzentry (maraviroc), 300 milligram tablets (NDA) 022-128 (Pfizer, Inc.), proposed for the treatment of antiretroviral-experienced patients with chemokine (c-c motif) receptor 5 (CCR5)--tropic human immunodeficiency virus (HIV)
Date: 4/24/2007

Committee: Antiviral Drugs Advisory Committee

2006

Topic: Clinical trial design issues in the development of products for the treatment of chronic hepatitis C infection
Date: 10/19-20/2006

Committee: Antiviral Drugs Advisory Committee

Topic: Radiesse, a sterile, non-pyrogenic, flexible, semi-solid cohesive granular implant containing calcium hydroxylapatite granules in a gel of glycerine, water and sodium carboxymethylcellulose, manufactured by BioForm Medical, Inc.
Date: 8/24/2006

Committee: General and Plastic Surgery Devices Panel

Topic: Proposed Studies to Support the Approval of Over-the-Counter (OTC) Home-Use HIV Test Kits
Date: 3/10/2006

Comittee: Blood Products Advisory Committee

Return to Index

2005

Topic: An approach for home-use rapid HIV test kits (for over-the-counter (OTC) availability of the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test for use with oral fluid specimens), and a committee update on: draft guidance on nucleic acid testing (NAT) for human immunodeficiency virus (HIV)-1 and hepatitis C virus (HCV): Testing, product disposition, and donor deferral and re-entry
Date: 11/3/2005

Committee: Blood Products Advisory Committee

Return to Index

Topic: Aptivus (Tipranavir) 250 milligrams (mg) capsules, new drug application (NDA) 021-814 (Boehringer Ingelheim Pharmaceuticals, Inc.), indicated for the treatment of patients with HIV.
Date: 5/19/2005

Committee: Antiviral Drugs Advisory Committee

Return to Index

2004

Topic: Review of Thailand HIV vaccine phase III trial for an HIV I recombinant canarypox-vectored vaccine and a recombinant gp 120 B/E CHO cells with alum vaccine.
Date: 9/23/2004

Committee: Vaccines and Related Biological Products Advisory Committee

Topic: Premarket approval application (PMA) for an injectable device intended for use in the correction of lipoatrophy of the face in human immunodeficiency virus (HIV) positive patients (Dermik Laboratories) (Poly L- Lactic Acid, Sculptra, also known in Europe as New Fill).
Date: 3/25/2004

Committee: General and Plastic Surgery Devices Panel (Center for Devices and Radiological Health)

Return to Index

2003

Topic: Clinical trial design issues in the development of topical microbicides for the reduction of HIV transmission.

Date: 8/20/2003

Committee: Antiviral Drugs Advisory Committee

Topic: Reyataz™ (atazanavir sulfate) capsules, new drug application (NDA) 21-567, (Bristol-Myers Squibb Company), for the treatment of human immunodeficiency virus infection.
Date: 5/13-14/2003

Committee: Antiviral Drugs Advisory Committee

Date: 5/14/2003

Topic: Issues related to the development of antiretroviral drugs in human immunodeficiency virus (HIV)-infected and HIV-exposed neonates younger than 4 weeks of age
Date 3/3/2003

Committee: Anti-Infective Drugs Advisory Committee, Pediatric Subcommittee

Return to Index

2002

There were no FDA advisory committee meetings directly related to HIV/AIDS during 2002

2001

Topic: Lentiviral vector gene transfer product for treatment of people with HIV
Date 10/24-25/2001

Committee: Biological Response Modifiers Advisory Committee

Topic: Viread™ (tenofovir disoproxil fumarate) Tablets, new drug application (NDA) 21-356 (Gilead Sciences) for the treatment of human immunodeficiency virus (HIV) infection,
Date: 10/3/2001

Committee: Antiviral Drugs Advisory Committee

Topics: Rapid HIV Tests and Serological Test Results

Date: 6/14-15/2001

Committee: Blood Products Advisory Committee

Topic: Valcyte (valganciclovir hydrochloride) tablets, 450mg, Syntex (USA) LLC, NDA 21-304, proposed for treatment of cytomegalovirus (CMV) retinitis in patients with acquired immunodeficiency syndrome (AIDS).
Date: 2/27/2001

Committee: Antiviral Drugs Advisory Committee

Topic: Clinical trial design issues for patients with HIV-1 infection who have limited therapeutic options
Date: 01/11/2001

Committee: Antiviral Drugs Advisory Committee

Return to Index

2000

Topic: The use of surrogate markers in early development of immunomodulatory agents for the treatment of patients with HIV.
Date: 10/16/2000

Committee: Antiviral Drugs Advisory Committee

Topic: FDA blood or plasma donor deferral policy related to men who have had sex with men (MSMs) -- Blood Donor Deferral for MSMs
Date: 9/14/2000

Committee: Blood Products Advisory Committee

Topic: The role of pharmacokinetic data in the evaluation of new formulations, alternative dosing regimens and new dosing combinations of approved antiretroviral drugs.
Date: 7/25/2000

Committee: Antiviral Drugs Advisory Committee

Return to Index

1999

Topic: The role of genotypic and phenotypic HIV resistance testing in antiretroviral drug development
Date: 11/2-3/1999

Committee: Antiviral Drugs Advisory Committee

Topic: Adefovir, new drug application (NDA) 20- 993, adefovir dipivoxil (Gilead Sciences Inc.), for the treatment of human immunodeficiency virus infection.
Date 11/1/1999

Committee: Antiviral Drugs Advisory Committee

Topic: Discussion of issues related to the potential applicability of information from non-U.S. studies of prevention of perinatal human imunodeficiency virus transmission to U.S. clinical settings.
Date: 10/4/1999

Committee: Antiviral Drugs Advisory Committee

Topic: Reclassification of Human Immunodeficiency Virus (HIV) drug sensitivity assays.
Date: 09/17/1999

Committee: Blood Products Advisory Committee

The agency described the general classification of biological products, and asked the committee for a recommendation for classification of viral resistance assays. The classification assignment determines how these assays are regulated by the agency.

Return to Index

1998

Topic: Ziagen (abacavir sulfate), new drug application (NDA) 20-977/20-978 to treat HIV infection
Date: 11/2/1998

Committee: Antiviral Drugs Advisory Committee

Transcript (Rich Text Format)
Transcript (PDF - 166 KB)

Topic: Presentations on general regulatory procedures and policies, including overview of the Food and Drug Administration Modernization Act of 1997
Date: 7/14/1998

Committee: Antiviral Drugs Advisory Committee

Transcript (PDF- 4 MB)

Topic: NTZ (nitazoxanide), new drug application (NDA) 20-871 for treatment of Cryptosporidiosis
Date: 5/6/1998

Committee: Antiviral Drugs Advisory Committee

Transcript (Rich Text Format)
Transcript (PDF - 12 MB)

Return to Index

1997

Topic: Utility of plasma HIV RNA as an endpoint in clinical trials for drugs to treat HIV infection, and review of pediatric HIV data
Date: 7/14-15/1997

Committee: Antiviral Drugs Advisory Committee

Transcript (PDF Format - 12 MB)

Topic: Zyrkamine (mitoguazone dihydrochloride, ILEX Oncology), indicated for treatment of AIDS-related non-Hodgkins lymphoma in patients who have been previously treated with at least one potentially curative regimen.
Date: 6/23/1997

Committee: Oncologic Drugs Advisory Committee

Transcript (Rich Text Format)
Transcript (PDF)
Additional Documents: Slides (PDF)

Return to Index

1996

Transcripts from 1996 meetings are available from the Freedom of Information Office.

Topic: Rescriptor (delavirdine), new drug application (NDA) 20-705 for the treatment of HIV infection
Date: 11/22/1996

Committee: Antiviral Drugs Advisory Committee

Transcripts from 1996 meetings are available from the Freedom of Information Office.

Topic: The use of microbicidal topical vaginal agents against sexually transmitted chlamydia trachomatis and Neisseria gonorrhoeae. Discussion on guidelines for the development of vaginal products for preventing the transmission of HIV. Discussion on proposals and guidances for clinical efficacy studies on marketed OTC vaginal spermicides.
Date: 11/20-22/1996

Committee: Joint meeting of the Nonprescription Drugs Advisory Committee, the Antiviral Drugs Advisory Committee, the Anti-Infective Drugs Advisory Committee and the Advisory Committee for Reproductive Health

Transcripts from 1996 meetings are available from the Freedom of Information Office.

Topic: Viramune (nevirapine), new drug application (NDA) 20-636 for the treatment of HIV infection
Date: 6/7/1996

Committee: Antiviral Drugs Advisory Committee

Transcripts from 1996 meetings are available from the Freedom of Information Office.

Topic: Vistide (cidofovir, intravenous), new drug application (NDA) 20-638 for the treatment of CMV retinitis
Date: 3/15/1996

Committee: Antiviral Drugs Advisory Committee joint meeting with Ophthalmic Drugs Subcommittee

Summary Minutes
Transcripts from 1996 meetings are available from the Freedom of Information Office.

Topic: Serostim (somatropin), new drug application (NDA) 20-604 for the treatment of AIDS wasting or cachexia
Date: 3/1/1996

Committee: Endocrinologic and Metabolic Drugs Advisory Committee joint meeting with Antiviral Drugs Advisory Committee

Transcripts from 1996 meetings are available from the Freedom of Information Office.

Topic: Crixivan (indinavir capsules), new drug application (NDA) 20-685 for the treatement of HIV infection
Date: 3/1/1996

Committee: Antiviral Drugs Advisory Committee

Transcripts from 1996 meetings are available from the Freedom of Information Office.

Topic: Norvir (ritonavir), new drug application (NDA) 20-659/20-68 for the treatement of HIV infection
Date: 2/29/1996

Committee: Antiviral Drugs Advisory Committee

Transcripts from 1996 meetings are available from the Freedom of Information Office.

Topic: Retrovir (zidovudine), new drug application (NDA) 19-665/19-919
Date: 2/28/1996

Committee: Antiviral Drugs Advisory Committee

Transcripts from 1996 meetings are available from the Freedom of Information Office.

Topic: Discussion of recent studies with nucleoside analogues for the treatment of HIV infection.
Date: 2/28/1996

Committee: Antiviral Drugs Advisory Committee

Data from AIDS Clinical Trials Group (ACTG) Study 175, the Delta studies, and other relevant studies. Data from Videx new drug application (NDA) 20-154, 20-155 and 20-156, Retrovir NDA 19-655 and 19-910 and HIVID NDA 20-199 were discussed.

Transcripts from 1996 meetings are available from the Freedom of Information Office.

Return to Index

horizontal rule

HIV/AIDS Home Page

FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA | Privacy | Accessibility

FDA Office of Special Health Issues